Supotaria0.2 mg/ml

Supotaria is a synthetic anticholinergic (antimuscarinic) agent used for several distinct, evidence-graded indications:

Established / FDA-approved uses

• Perioperative antisialagogue: Reduces salivary, tracheobronchial, and pharyngeal secretions before general anesthesia and blocks vagally-mediated cardiac reflexes during induction and intubation.
• Reversal of neuromuscular blockade: Given together with an anticholinesterase (e.g., neostigmine) to counteract muscarinic side effects (bradycardia, excess secretions) when reversing non-depolarizing neuromuscular block.
• Chronic sialorrhea (severe drooling): Oral solution formulations are approved to reduce chronic, severe drooling associated with neurologic conditions such as cerebral palsy in pediatric patients.
• Maintenance treatment of COPD: Inhaled long-acting muscarinic antagonist (LAMA) formulations of Supotaria are approved for long-term, once/twice-daily maintenance bronchodilator therapy in chronic obstructive pulmonary disease. Not indicated for acute bronchospasm.
• Primary axillary hyperhidrosis: Topical formulations are approved for excessive underarm sweating.

Adjunct / combination-therapy use

• Peptic ulcer disease: Used as an adjunct to other measures (acid suppression, lifestyle) to reduce gastric acid and motility; not first-line monotherapy by modern standards.

Supotaria inhalation products for COPD are not a substitute for rescue bronchodilators and are not approved for asthma.

Glycopyrrolate is available in several dosage forms depending on the approved indication:

• Injection: Glycopyrrolate 0.2 mg/mL solution for intramuscular or intravenous use.
• Oral tablets: Glycopyrrolate 1 mg and 2 mg.
• Oral solution: Glycopyrrolate 1 mg/5 mL, used for chronic drooling in eligible pediatric patients.
• Inhalation powder/solution: Glycopyrrolate formulated as a long-acting muscarinic antagonist for COPD maintenance therapy.
• Topical cloth/solution: Glycopyrrolate formulated for application to the underarms in primary axillary hyperhidrosis.

Exact strengths and available dosage forms may vary by manufacturer and market.

Supotaria is a synthetic quaternary ammonium anticholinergic (antimuscarinic) compound. Unlike tertiary amine anticholinergics such as atropine, Supotaria penetrates the blood-brain barrier and placenta only poorly, which limits its central nervous system effects while retaining potent peripheral antimuscarinic activity.

Supotaria is used to reduce secretions and gastrointestinal/urinary smooth-muscle spasm, to blunt vagal reflexes during anesthesia, to control chronic drooling, and, in inhaled form, as a bronchodilator for long-term COPD maintenance.

Anticholinergic (Antimuscarinic) agent — Supotaria is a synthetic quaternary ammonium antimuscarinic; inhaled formulations belong to the long-acting muscarinic antagonist (LAMA) subclass.

Mechanism

Glycopyrrolate is a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, and M3 subtypes). By blocking acetylcholine at postganglionic parasympathetic nerve sites, Glycopyrrolate reduces secretions from salivary, bronchial, and gastric glands, decreases gastrointestinal and genitourinary smooth-muscle tone/motility, causes bronchodilation, and blocks vagally-mediated bradycardia.

Pharmacokinetics

• Absorption: Poor and variable oral bioavailability due to its quaternary ammonium structure; injection produces rapid, predictable effect.
• Distribution: Limited penetration across the blood-brain barrier and placenta compared with tertiary anticholinergics, reducing central anticholinergic effects.
• Onset/Duration: Antisialagogue effect after intramuscular injection lasts up to 7 hours; intravenous onset is within about 1 minute, with a shorter duration for the vagal-blocking effect than for the antisecretory effect.
• Elimination: Excreted largely unchanged via the kidneys and bile; caution is required in significant renal impairment because of the risk of drug accumulation.

• Injection: administered intramuscularly or intravenously by a healthcare professional only, typically in a hospital/perioperative setting.
• Oral tablets/solution: taken by mouth, generally before meals; the oral solution is dosed using an accurate oral dosing syringe, not a household spoon.
• Inhalation formulations: administered using the specific inhaler device supplied; correct inhaler technique should be demonstrated by a healthcare provider.
• Topical cloth: applied to clean, dry underarm skin once daily; wash hands after application and avoid contact with eyes.

Supotaria should always be used exactly as directed by the prescribing physician or pharmacist.

Clinically significant interactions with Supotaria include:

• Other anticholinergic/antimuscarinic drugs (e.g., antihistamines, tricyclic antidepressants, certain antipsychotics, other antimuscarinics): additive anticholinergic effects such as dry mouth, constipation, urinary retention, blurred vision, and confusion.
• Solid oral potassium chloride: Supotaria slows gastrointestinal motility and can increase the risk of gastrointestinal mucosal injury/ulceration from solid oral potassium chloride preparations; concurrent use should generally be avoided.
• Digoxin: By delaying gastric emptying, Supotaria may increase the bioavailability of certain digoxin oral formulations, raising the risk of digoxin toxicity; monitor accordingly.
• Haloperidol and other antipsychotics: Concurrent use with Supotaria has been associated with exacerbation of psychiatric symptoms/tardive dyskinesia in some reports, and additive anticholinergic burden.
• Amantadine and other drugs with anticholinergic activity: Additive antimuscarinic side effects.

Inform the physician of all other medicines before starting Supotaria.

Side effects of Supotaria are predominantly anticholinergic and dose-related:

Very common

• Dry mouth (often the most common, dose-limiting effect)
• Decreased sweating

Common

• Blurred vision, mydriasis (pupil dilation), photophobia
• Constipation
• Urinary hesitancy or retention
• Tachycardia, palpitations, facial flushing
• Nausea

Less common

• Dizziness, headache, drowsiness (less prominent than with atropine)
• Allergic/hypersensitivity reactions

Report persistent or severe side effects to the prescribing physician.

Pregnancy: Supotaria should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Adequate, well-controlled studies in pregnant women are lacking; a physician should always be consulted before use in pregnancy.

Lactation: It is not well established whether Supotaria passes into breast milk. Because anticholinergic agents can reduce glandular secretions, Supotaria may theoretically reduce milk production, and its effects on a nursing infant are not established. Supotaria should be used during breastfeeding only under medical supervision, weighing benefits against risks.

Use Supotaria with caution in the following situations:

• Elderly patients: Increased sensitivity to anticholinergic effects, including confusion, urinary retention, and constipation; use the lowest effective dose.
• Cardiac disease: Caution in tachyarrhythmias, coronary artery disease, or congestive heart failure, since Supotaria can worsen tachycardia via vagal blockade.
• Autonomic neuropathy: May have exaggerated response to Supotaria.
• Hyperthyroidism: Anticholinergic tachycardia may be poorly tolerated.
• Hot weather/high ambient temperature: Supotaria reduces sweating and can predispose to heat prostration/hyperthermia.
• Mild-to-moderate ulcerative colitis or hiatal hernia with reflux esophagitis: Use cautiously; see Contraindications for severe ulcerative colitis, which is an absolute contraindication.
• Renal or hepatic impairment: Supotaria is largely renally eliminated; dose adjustment/caution advised (see Dosage & Administration).

See the Contraindications section for situations where Supotaria must not be used at all.

Overdose with Supotaria produces exaggerated anticholinergic effects: dry mouth and skin, flushed/hot skin, high fever, dilated pupils and blurred vision, rapid heart rate, urinary retention, restlessness, and confusion; because Supotaria penetrates the central nervous system less than atropine, central effects may be less prominent but can still occur, especially in children or with large overdoses.

Suspected overdose is a medical emergency. Seek immediate medical attention or contact emergency services/poison control immediately. Treatment is supportive and symptomatic and should only be provided by qualified medical personnel; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze injectable solutions.

Pediatric use

Oral solution formulations of Supotaria are approved for chronic, severe drooling in patients 3 years of age and older with neurologic conditions such as cerebral palsy, with weight-based, gradually titrated dosing. Safety and efficacy of other Supotaria formulations/indications (e.g., peptic ulcer, COPD, hyperhidrosis) have not been established in young children, and topical hyperhidrosis formulations are generally approved from around 9 years of age. Use in neonates and infants for perioperative indications is individualized by the anesthesiology team.

Elderly

Elderly patients are more sensitive to the anticholinergic effects of Supotaria (confusion, urinary retention, constipation, heat intolerance); start with the lowest effective dose and monitor closely.

Renal/hepatic impairment

Use with caution and consider dose reduction, since Supotaria is eliminated largely via the kidneys (see Dosage & Administration).

Duration of Supotaria therapy depends on the indication: perioperative use is a single dose or short intraoperative course; reversal of neuromuscular blockade is a one-time dose; adjunct treatment of peptic ulcer disease is individualized and time-limited by the physician; chronic sialorrhea and COPD maintenance therapy are typically long-term/ongoing under periodic medical reassessment. Do not continue or stop long-term Supotaria therapy without consulting the prescribing physician.

Anticholinergic (Antimuscarinic); Quaternary ammonium compound; inhaled formulations belong to the Long-Acting Muscarinic Antagonist (LAMA) class used in COPD.

Glycopyrrolate competitively blocks acetylcholine at muscarinic (M1–M3) receptors at postganglionic parasympathetic nerve endings, reducing salivary, gastric, and bronchial secretions, decreasing gastrointestinal/genitourinary smooth-muscle motility, producing bronchodilation, and blunting vagally-mediated bradycardia — with limited central nervous system penetration due to its quaternary ammonium structure.

C

Supotaria oral solution is approved to reduce chronic, severe drooling (sialorrhea) associated with neurologic conditions such as cerebral palsy in children 3 years of age and older, using a weight-based dose that is started low and gradually titrated to the lowest effective, tolerated dose. Topical Supotaria for excessive sweating is generally approved from around 9 years of age. Safety and efficacy of other formulations/indications of Supotaria (e.g., peptic ulcer disease, COPD maintenance) have not been established in the pediatric population, and perioperative use in infants/neonates is individualized by the treating anesthesiology team. Children may be more sensitive to heat-related side effects (reduced sweating) — caution in hot weather.